Display options
Cite
Lee HH, Hsu PC, Lin TH, et al. Nicorandil-induced hyperkalemia in a uremic patient. Case Rep Med. 2012;2012:812178doi: 10.1155/2012/812178.
Lee, H. H., Hsu, P. C., Lin, T. H., Lai, W. T., & Sheu, S. H. (2012). Nicorandil-induced hyperkalemia in a uremic patient. Case reports in medicine, 2012812178. https://doi.org/10.1155/2012/812178
Lee, Hung-Hao, et al. "Nicorandil-induced hyperkalemia in a uremic patient." Case reports in medicine vol. 2012 (2012): 812178. doi: https://doi.org/10.1155/2012/812178
Lee HH, Hsu PC, Lin TH, Lai WT, Sheu SH. Nicorandil-induced hyperkalemia in a uremic patient. Case Rep Med. 2012;2012:812178. doi: 10.1155/2012/812178. Epub 2012 Oct 18. PMID: 23118767; PMCID: PMC3483680.
Copy Download .nbib Format: NLM
Share it on

Case Rep Med. 2012;2012:812178. doi: 10.1155/2012/812178. Epub 2012 Oct 18.

Nicorandil-induced hyperkalemia in a uremic patient.

Case reports in medicine

Hung-Hao Lee, Po-Chao Hsu, Tsung-Hsien Lin, Wen-Ter Lai, Sheng-Hsiung Sheu

Affiliations

  1. Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, No. 100, Tzyou 1st Road, Kaohsiung 80756, Taiwan.

PMID: 23118767 PMCID: PMC3483680 DOI: 10.1155/2012/812178

Abstract

Nicorandil is an antianginal agent with nitrate-like and ATP-sensitive potassium channel activator properties. After activation of potassium channels, potassium ions are expelled out of the cells, which lead to membrane hyperpolarization, closure of voltage-gated calcium channels, and finally vasodilation. We present a uremic case suffering from repeated junctional bradycardia, especially before hemodialysis. After detailed evaluation, nicorandil was suspected to be the cause of hyperkalemia which induced bradycardia. This case reminds us that physicians should be aware of this potential complication in patients receiving ATP-sensitive potassium channel activator.

References

  1. J Cardiovasc Pharmacol. 1992;20 Suppl 3:S93-102 - PubMed
  2. Lancet. 2002 Apr 13;359(9314):1269-75 - PubMed
  3. Cardiovasc Drugs Ther. 1995 Mar;9 Suppl 2:229-36 - PubMed
  4. J Cardiovasc Pharmacol. 1992;20 Suppl 3:S34-44 - PubMed
  5. Int J Cardiol. 1994 May;44(3):203-15 - PubMed
  6. Am J Physiol Heart Circ Physiol. 2003 Sep;285(3):H921-30 - PubMed
  7. Physiol Rev. 1997 Oct;77(4):1165-232 - PubMed
  8. Curr Vasc Pharmacol. 2003 Oct;1(3):251-8 - PubMed
  9. Metabolism. 1986 Nov;35(11):981-3 - PubMed
  10. Eur J Clin Pharmacol. 1992;42(2):203-7 - PubMed
  11. Pharmacoepidemiol Drug Saf. 1999 May;8(3):197-205 - PubMed
  12. Cardiovasc Drugs Ther. 1997 Mar;11(1):81 - PubMed
  13. Lancet. 2005 May 28-Jun 3;365(9474):1873-5 - PubMed
  14. Eur Heart J. 1993 Jul;14 Suppl B:48-52 - PubMed

Publication Types